Biotech InnovationThe study applied six proteomic clocks to serum proteomes from a published phase 2a trial of rentosertib, an AI-designed TNIK inhibitor being developed for idiopathic pulmonary fibrosis and aging-related biology. All six clocks moved in the same direction, but the paper also highlights a central limitation for the field: biomarker shifts still need contextual biological analysis before they can be read as clean anti-aging effects.
Emily Carter·Sep 7, 2026
Regulatory & PolicyThe new recommendations cover how clinicians should evaluate tactical athletes with cardiovascular disease or at risk of developing it in light of their professional demands. The guidance extends sports cardiology principles into service roles where sudden exertion, environmental extremes and stress can change the consequences of even common risk factors.
Emily Carter·Sep 5, 2026 
Biopharmaceutical IndustryZanvastro, formerly zilganersen, is an antisense oligonucleotide that lowers production of GFAP, the protein that accumulates in Alexander disease. For Ionis, the approval adds a commercial foothold in neurology as it prepares other RNA-based programs, including its Phase 3 effort in Angelman syndrome.
Emily Carter·Sep 4, 2026 
Regulatory & PolicyThe applications put AMT-130 on track to become the first genetic treatment for Huntington’s disease if regulators agree that three-year Phase 1/2 data can support accelerated approval. The bigger signal is regulatory: the case tests how far the FDA will go in accepting external controls and small-population gene therapy data after a public dispute inside the agency earlier this year.
Emily Carter·Sep 2, 2026 
Biopharmaceutical IndustryBioXcel moved into bankruptcy after warning it lacked funds to operate through the end of August, even after securing a loan earlier this week. Teva’s bid includes $57.5 million upfront and up to $67.5 million in milestones, with the largest payout contingent on BXCL501 winning approval by the current Nov. 14 PDUFA date.
Emily Carter·Aug 28, 2026 
Regulatory & PolicyHospital systems are remaking operations after the passage of a law that will cut nearly $1 trillion in Medicaid funding over the next decade, while lobbyists in Washington search for ways to mitigate the damage. The opening, according to people familiar with the effort, is less about a clean repeal now than about carving out narrower fixes, favorable rule changes and other federal payment support while the politics of the cuts harden.
Emily Carter·Aug 27, 2026 
Biopharmaceutical IndustryThe FDA approved Ziihera for newly diagnosed patients with unresectable locally advanced or metastatic gastroesophageal adenocarcinoma with HER2 mutations. For Jazz, the label expansion shifts attention from regulatory risk to launch execution in what Truist projects as the drug’s biggest commercial setting.
Emily Carter·Aug 26, 2026 
Regulatory & PolicyAccording to CNBC, the FDA is considering new deputy commissioner positions that would report to the commissioner. The potential change comes as President Donald Trump has nominated Heidi Overton for the top job and as industry watchers look for steadier leadership across the agency’s review functions.
Emily Carter·Aug 26, 2026 Regulatory & PolicyState officials said the two people who died were unvaccinated residents of Lancaster County, and Pennsylvania has now counted nearly 400 measles cases this year. The deaths add pressure to a vaccination debate that has intensified as national coverage rates fall below the level typically needed to prevent outbreaks.
Emily Carter·Aug 25, 2026 
Regulatory & PolicyRGX-121 had regained a possible path under accelerated approval in June after the FDA earlier rejected the filing and asked for a new study, more patients and a placebo arm. The new hold shifts the focus from filing strategy back to safety interpretation and longer-term follow-up in an ultra-rare disease setting with limited imaging history.
Emily Carter·Aug 24, 2026 
Healthcare InvestmentAbcuro is using fresh capital to narrow its development strategy around a subgroup that showed a stronger signal in an earlier study. The raise suggests investors still see a regulatory path for ulviprubart despite a setback in a trial that had been expected to support submission.
Emily Carter·Aug 23, 2026 
Medical TechnologyNew long-term U.K. data gave focal therapy supporters fresh evidence, including a reported 0.1% prostate cancer mortality rate 10 years after treatment. Even so, debate persists because randomized comparisons with standard treatment remain limited and real-world use extends beyond the patients guidelines say should receive it.
Emily Carter·Aug 23, 2026 